# Jade Biosciences (JBIO) — News

JBIO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/jbio/news

## Recent headlines

- [Jade Biosciences: Phase 1 trial for Jade301 to begin in Q4 2026; interim data in H2 2027](https://www.ainvest.com/news/jade-biosciences-phase-1-trial-jade301-q4-2026-interim-data-h2-2027-2609) — AInvest Wire, Sep 30, 2026
  Jade Biosciences (JBIO) announced that its Phase 1 clinical trial for JADE301, a half-life–extended, subcutaneous anti–IFN-β candidate for dermatomyositis, is expected to begin in the fourth quarter of 2026. Interim data from the trial is anticipated in the second half of 2027. The company also…
- [Jade Biosciences, - Jade301 well tolerated in non-human primates at all subcutaneous doses](https://www.ainvest.com/news/jade-biosciences-jade301-tolerated-human-primates-subcutaneous-doses-2609) — AInvest Wire, Sep 30, 2026
- [Jade Biosciences, - Jade301 shows about 25-day half-life and predictable muscle distribution in primates](https://www.ainvest.com/news/jade-biosciences-jade301-shows-25-day-life-predictable-muscle-distribution-primates-2609) — AInvest Wire, Sep 30, 2026
- [Jade Biosciences, - Jade301 demonstrates high-affinity, selective IFN-β binding and greater potency than Dazukibart](https://www.ainvest.com/news/jade-biosciences-jade301-demonstrates-high-affinity-selective-ifn-binding-greater-potency-dazukibart-2609) — AInvest Wire, Sep 30, 2026
- [Jade Biosciences, Inc.: Clear Street raises target price to $48 from $25](https://www.ainvest.com/news/jade-biosciences-clear-street-raises-target-price-48-25-2609) — AInvest Wire, Sep 4, 2026
  Jade Biosciences, Inc. (NASDAQ: JBio) has seen a notable increase in its stock price, rising $2.64, or 15.70% , since the previous market close, with shares opening at $17.90. The company, which focuses on developing therapies for rare cardiopulmonary and autoimmune diseases, has drawn attention…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).